Literature DB >> 8613635

Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5).

S Vrtala1, M Susani, W R Sperr, P Valent, S Laffer, C Dolecek, D Kraft, R Valenta.   

Abstract

BACKGROUND: Grass pollen allergens belong to the potent elicitors of type I allergy. Approximately 40% of allergic individuals display IgE reactivity with grass pollen allergens. In previous studies we have reported the complementary DNA cloning and expression in Escherichia coli of three of the most relevant timothy grass pollen allergens: Phl p 1, Phl p 2, and Phl p 5.
OBJECTIVE: To achieve high level expression of immunologically active timothy grass pollen allergens in E. coli, the cDNAs were inserted into expression plasmids.
METHODS: The three recombinant grass pollen allergens were expressed at high levels in E. coli as recombinant nonfusion proteins, purified by conventional protein chemical methods and tested for their IgE-binding capacity by immunoblot and ELISA, as well as in histamine release assays.
RESULTS: Milligram amounts of pure recombinant allergens were obtained from cultured E. coli. IgE binding to purified recombinant Phl p 1, Phl p 2, and Phl p 5 could be demonstrated by immunoblot and ELISA. With ELISAs the percentage of grass pollen-specific IgE directed against the individual recombinant allergens could be estimated. In addition, the purified recombinant timothy grass pollen allergens induced dose-dependent and specific histamine release from patients' blood basophils.
CONCLUSION: Purified recombinant timothy grass pollen allergens represent useful tools for diagnosis and therapy of grass pollen allergy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613635     DOI: 10.1016/s0091-6749(96)80156-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

1.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 3.  New strategies for allergen T cell epitope identification: going beyond IgE.

Authors:  Véronique Schulten; Bjoern Peters; Alessandro Sette
Journal:  Int Arch Allergy Immunol       Date:  2014-11-15       Impact factor: 2.749

4.  Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy.

Authors:  Véronique Schulten; Victoria Tripple; John Sidney; Jason Greenbaum; April Frazier; Rafeul Alam; David Broide; Bjoern Peters; Alessandro Sette
Journal:  J Allergy Clin Immunol       Date:  2014-07-16       Impact factor: 10.793

Review 5.  Challenges for allergy diagnosis in regions with complex pollen exposures.

Authors:  Domingo Barber; Araceli Díaz-Perales; Mayte Villalba; Tomas Chivato
Journal:  Curr Allergy Asthma Rep       Date:  2015-02       Impact factor: 4.806

6.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

7.  Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.

Authors:  Susanne Vrtala; Monika Fohr; Raffaela Campana; Christian Baumgartner; Peter Valent; Rudolf Valenta
Journal:  Vaccine       Date:  2011-01-05       Impact factor: 3.641

8.  A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

Authors:  Katarzyna Niespodziana; Margarete Focke-Tejkl; Birgit Linhart; Vera Civaj; Katharina Blatt; Peter Valent; Marianne van Hage; Hans Grönlund; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2011-03-16       Impact factor: 10.793

9.  Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy.

Authors:  Birgit Linhart; Sinda Bigenzahn; Arnulf Hartl; Christian Lupinek; Josef Thalhamer; Rudolf Valenta; Thomas Wekerle
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

10.  Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.

Authors:  Margarete Focke-Tejkl; Raffaela Campana; Renate Reininger; Christian Lupinek; Katharina Blatt; Peter Valent; Tea Pavkov-Keller; Walter Keller; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2013-10-31       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.